



## Grifols – Recall of Gamunex<sup>®</sup>-C (immune globulin [human])

- On February 21, 2019, [Grifols announced](#) a voluntary, consumer-level recall of one lot of [Gamunex-C \(immune globulin \[human\]\)](#) injection due to a higher rate of allergic/hypersensitivity type reactions, a small number of which were considered medically significant.
  - Hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with IVIG products.
- The recalled lot was distributed starting December 15, 2018:

Product Description	NDC#	Lot# / Expiration Date
Gamunex-C 10%, 20 gm/200 mL	13533-0800-24	A1GLC01372 / 11/2/2021

- Gamunex-C is indicated for the treatment of primary humoral immunodeficiency in patients 2 years of age and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Gamunex-C is also indicated for the treatment of adults and children with idiopathic thrombocytopenic purpura (ITP) to raise platelet counts to prevent bleeding or to allow a patient with ITP to undergo surgery and for the treatment of chronic inflammatory demyelinating polyneuropathy in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled Gamunex-C.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
- For more information regarding this recall, contact Grifols US Clinical Communications at **1-800-520-2807**.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.